Trial Outcomes & Findings for GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States) (NCT NCT01671007)

Last Updated: 2020-12-31

Results Overview

Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate.

Recruitment status

COMPLETED

Target enrollment

10471 participants

Primary outcome timeframe

From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

Results posted on

2020-12-31

Participant Flow

This study investigated characteristics of patients with non-valvular atrial fibrillation influencing the choice of antithrombotic treatment for the prevention of stroke, and the safety and effectiveness of dabigatran versus Vitamin K Antagonist for up to 3-year follow-up period.

All subjects were screened for eligibility prior to participation in the study. Subjects attended a participating site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria.

Participant milestones

Participant milestones
Measure	Dabigatran Etexilate - Baseline Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Rivaroxaban - Baseline Patients who were prescribed Rivaroxaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Apixaban - Baseline Patients who were prescribed Apixaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Edoxaban - Baseline Patients who were prescribed Edoxaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Acetylsalicylic Acid (ASA) - Baseline Patients who were prescribed Acetylsalicylic acid (ASA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Antiplts Other Than ASA - Baseline Patients who were prescribed Antiplts other than Acetylsalicylic acid (ASA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	No Treatment - Baseline Patients who were prescribed no treatment at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Combinations With Oral Anticoagulants - Baseline Patients who were prescribed the treatments with combinations with oral anticoagulants at baseline were included in this group. This group of patients were not included in the safety analysis as no specific treatment can be defined. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Overall Study STARTED	2089	2834	2033	2214	180	513	80	526	2
Overall Study All Eligible	2066	2758	2008	2197	180	507	79	507	2
Overall Study COMPLETED	1768	2183	1667	1846	155	401	59	394	2
Overall Study NOT COMPLETED	321	651	366	368	25	112	21	132	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Dabigatran Etexilate - Baseline Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Rivaroxaban - Baseline Patients who were prescribed Rivaroxaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Apixaban - Baseline Patients who were prescribed Apixaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Edoxaban - Baseline Patients who were prescribed Edoxaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Acetylsalicylic Acid (ASA) - Baseline Patients who were prescribed Acetylsalicylic acid (ASA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Antiplts Other Than ASA - Baseline Patients who were prescribed Antiplts other than Acetylsalicylic acid (ASA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	No Treatment - Baseline Patients who were prescribed no treatment at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Overall Study Other reasons than listed	166	373	197	228	14	71	17	66
Overall Study Withdrawal by Subject	36	59	53	58	4	15	1	19
Overall Study Lost to Follow-up	93	142	91	63	7	20	2	28
Overall Study No end of study case report form	3	1	0	2	0	0	0	0
Overall Study Not eligible	23	76	25	17	0	6	1	19

Baseline Characteristics

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Dabigatran Etexilate - Baseline n=2066 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2758 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Rivaroxaban - Baseline n=2008 Participants Patients who were prescribed Rivaroxaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Apixaban - Baseline n=2197 Participants Patients who were prescribed Apixaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Edoxaban - Baseline n=180 Participants Patients who were prescribed Edoxaban at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Acetylsalicylic Acid (ASA) - Baseline n=507 Participants Patients who were prescribed Acetylsalicylic acid (ASA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Antiplts Other Than ASA - Baseline n=79 Participants Patients who were prescribed Antiplts other than Acetylsalicylic acid (ASA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	No Treatment - Baseline n=507 Participants Patients who were prescribed no treatment at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Combinations With Oral Anticoagulants - Baseline n=2 Participants Patients who were prescribed the treatments with combinations with oral anticoagulants at baseline were included in this group. This group of patients were not included in the safety analysis as no specific treatment can be defined. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Total n=10304 Participants Total of all reporting groups
Age, Continuous	71.3 Years STANDARD_DEVIATION 9.4 • n=5 Participants	72.8 Years STANDARD_DEVIATION 9.5 • n=7 Participants	71.1 Years STANDARD_DEVIATION 10.1 • n=5 Participants	73.3 Years STANDARD_DEVIATION 9.8 • n=4 Participants	73.3 Years STANDARD_DEVIATION 9.2 • n=21 Participants	70.5 Years STANDARD_DEVIATION 12.4 • n=10 Participants	74.2 Years STANDARD_DEVIATION 11.1 • n=115 Participants	68.7 Years STANDARD_DEVIATION 12.5 • n=24 Participants	71.5 Years STANDARD_DEVIATION 0.7 • n=42 Participants	72.0 Years STANDARD_DEVIATION 10.1 • n=42 Participants
Sex: Female, Male Female	942 Participants n=5 Participants	1252 Participants n=7 Participants	894 Participants n=5 Participants	990 Participants n=4 Participants	86 Participants n=21 Participants	234 Participants n=10 Participants	25 Participants n=115 Participants	246 Participants n=24 Participants	1 Participants n=42 Participants	4670 Participants n=42 Participants
Sex: Female, Male Male	1124 Participants n=5 Participants	1506 Participants n=7 Participants	1114 Participants n=5 Participants	1207 Participants n=4 Participants	94 Participants n=21 Participants	273 Participants n=10 Participants	54 Participants n=115 Participants	261 Participants n=24 Participants	1 Participants n=42 Participants	5634 Participants n=42 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	5 Participants n=5 Participants	14 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	21 Participants n=42 Participants
Race/Ethnicity, Customized Asian	4 Participants n=5 Participants	4 Participants n=7 Participants	7 Participants n=5 Participants	7 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	25 Participants n=42 Participants
Race/Ethnicity, Customized Black/African American	4 Participants n=5 Participants	6 Participants n=7 Participants	9 Participants n=5 Participants	9 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	31 Participants n=42 Participants
Race/Ethnicity, Customized Native Hawaiian/Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race/Ethnicity, Customized White	1792 Participants n=5 Participants	2526 Participants n=7 Participants	1735 Participants n=5 Participants	1835 Participants n=4 Participants	178 Participants n=21 Participants	430 Participants n=10 Participants	75 Participants n=115 Participants	482 Participants n=24 Participants	2 Participants n=42 Participants	9055 Participants n=42 Participants
Race/Ethnicity, Customized Other	7 Participants n=5 Participants	9 Participants n=7 Participants	4 Participants n=5 Participants	6 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=10 Participants	0 Participants n=115 Participants	2 Participants n=24 Participants	0 Participants n=42 Participants	31 Participants n=42 Participants
Race/Ethnicity, Customized Missing	254 Participants n=5 Participants	199 Participants n=7 Participants	253 Participants n=5 Participants	339 Participants n=4 Participants	0 Participants n=21 Participants	71 Participants n=10 Participants	3 Participants n=115 Participants	22 Participants n=24 Participants	0 Participants n=42 Participants	1141 Participants n=42 Participants

PRIMARY outcome

Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

Population: Restricted patient set: the set consists of all eligible patients who were within the region of propensity score (PS) overlap excluding patients in the non-overlapping tails of the propensity score distribution. The restricted patient set was defined for dabigatran etexilate and vitamin K antagonist patients only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction, Life-threatening Bleeding Events and Vascular Death)	2.30 Events per 100 person-years Interval 1.86 to 2.73	3.02 Events per 100 person-years Interval 2.54 to 3.54

PRIMARY outcome

Incidence rate of vascular composite outcome including events of stroke, systemic embolism, myocardial infarction and vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Vascular Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction and Vascular Death)	1.91 Events per 100 person-years Interval 1.52 to 2.32	2.36 Events per 100 person-years Interval 1.93 to 2.82

PRIMARY outcome

Incidence rate of stroke or systemic embolism on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Stroke or Systemic Embolism	0.69 Events per 100 person-years Interval 0.45 to 0.94	1.01 Events per 100 person-years Interval 0.76 to 1.3

PRIMARY outcome

Incidence rate of stroke on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Stroke is an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke included ischemic or hemorrhagic or uncertain classification.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Stroke	0.64 Events per 100 person-years Interval 0.42 to 0.89	0.96 Events per 100 person-years Interval 0.7 to 1.22

PRIMARY outcome

Incidence rate of transient ischaemic attack (TIA) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Transient Ischaemic Attack (TIA)	0.30 Events per 100 person-years Interval 0.16 to 0.47	0.26 Events per 100 person-years Interval 0.12 to 0.41

PRIMARY outcome

Incidence rate of systemic embolism (SEE) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Systemic Embolism (SEE)	0.07 Events per 100 person-years Interval 0.0 to 0.16	0.06 Events per 100 person-years Interval 0.0 to 0.14

PRIMARY outcome

Incidence rate of pulmonary embolism (PE) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Pulmonary Embolism (PE)	0.09 Events per 100 person-years Interval 0.02 to 0.18	0.06 Events per 100 person-years Interval 0.0 to 0.14

PRIMARY outcome

Incidence rate of major bleeding events on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Major bleeding was defined as meeting one or more of the following criteria: Overt bleeding associated with a reduction in haemoglobin of at least 20 grams per liter or leading to a transfusion of at least 2 units of blood or packed cells; Symptomatic bleeding in a critical area or organ: Intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding or pericardial bleeding; Life-threatening bleeding.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Major Bleeding Events	0.73 Events per 100 person-years Interval 0.49 to 0.98	1.42 Events per 100 person-years Interval 1.09 to 1.75

PRIMARY outcome

Incidence rate of life-threatening bleeding events on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Life-threatening bleeding was defined as meeting one or more of the following criteria: Symptomatic intracranial bleed; Reduction in haemoglobin of at least 50 grams per liter; Transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of intravenous inotropic agents; Necessitated surgical intervention; Fatal bleeding.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Life-threatening Bleeding Events	0.50 Events per 100 person-years Interval 0.31 to 0.71	1.04 Events per 100 person-years Interval 0.77 to 1.34

PRIMARY outcome

Incidence rate of vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Vascular Death	0.76 Events per 100 person-years Interval 0.51 to 1.02	1.00 Events per 100 person-years Interval 0.73 to 1.29

PRIMARY outcome

Incidence rate of myocardial infarction on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of Myocardial Infarction	0.34 Events per 100 person-years Interval 0.18 to 0.53	0.45 Events per 100 person-years Interval 0.27 to 0.64

PRIMARY outcome

Incidence rate of all-cause death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only.

Outcome measures

Outcome measures
Measure	Dabigatran Etexilate - Baseline n=1946 Participants Patients who were prescribed Dabigatran etexilate at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.	Vitamin K Antagonist (VKA) - Baseline n=2509 Participants Patients who were prescribed Vitamin K Antagonist (VKA) at baseline were included in this group. Patients can take other Antithrombotic treatments later during the study. Patients who were newly diagnosed non-valvular Atrial Fibrillation (AF) less than 3 months before the baseline visits (less than 4.5 months before baseline visit for Latin America) and who were at risk for stroke in a real-life setting. Antithrombotic treatments were used according to local practice for stroke prevention. The choice of antithrombotic agent and dosing was at the discretion of the treating physician.
Incidence Rate of All-cause Death	2.08 Events per 100 person-years Interval 1.69 to 2.51	3.27 Events per 100 person-years Interval 2.8 to 3.77

Adverse Events

Dabigatran Etexilate - at Least Once During the Study

Serious events: 79 serious events

Other events: 0 other events

Deaths: 116 deaths

Vitamin K Antagonist (VKA) - at Least Once During the Study

Serious events: 157 serious events

Other events: 0 other events

Deaths: 264 deaths

Rivaroxaban - at Least Once During the Study

Serious events: 92 serious events

Other events: 0 other events

Deaths: 166 deaths

Apixaban - at Least Once During the Study

Serious events: 99 serious events

Other events: 0 other events

Deaths: 207 deaths

Edoxaban - at Least Once During the Study

Serious events: 10 serious events

Other events: 0 other events

Deaths: 17 deaths

Acetylsalicylic Acid (ASA) - at Least Once During the Study

Serious events: 70 serious events

Other events: 0 other events

Deaths: 141 deaths

Antiplts Other Than ASA - at Least Once During the Study

Serious events: 14 serious events

Other events: 0 other events

Deaths: 33 deaths

Serious adverse events

Serious adverse events
Measure	Dabigatran Etexilate - at Least Once During the Study n=2385 participants at risk All patients received at least once dabigatran etexilate during the study were included in the group. Adverse events which happened when the patients received dabigatran etexilate were reported in this group. Patients can take any Antithrombotic treatments during the study. Adverse events were reported in the treatment group a patient actually received when the adverse events happened. Hence, the treatment groups in the adverse events section are not mutually exclusive.	Vitamin K Antagonist (VKA) - at Least Once During the Study n=3258 participants at risk All patients received at least once Vitamin K Antagonist (VKA) during the study were included in the group. Adverse events which happened when the patients received Vitamin K Antagonist (VKA) were reported in this group. Patients can take any Antithrombotic treatments during the study. Adverse events were reported in the treatment group a patient actually received when the adverse events happened. Hence, the treatment groups in the adverse events section are not mutually exclusive.	Rivaroxaban - at Least Once During the Study n=2576 participants at risk All patients received at least once Rivaroxaban during the study were included in the group. Adverse events which happened when the patients received Rivaroxaban were reported in this group. Patients can take any Antithrombotic treatments during the study. Adverse events were reported in the treatment group a patient actually received when the adverse events happened. Hence, the treatment groups in the adverse events section are not mutually exclusive.	Apixaban - at Least Once During the Study n=2934 participants at risk All patients received at least once Apixaban during the study were included in the group. Adverse events which happened when the patients received Apixaban were reported in this group. Patients can take any Antithrombotic treatments during the study. Adverse events were reported in the treatment group a patient actually received when the adverse events happened. Hence, the treatment groups in the adverse events section are not mutually exclusive.	Edoxaban - at Least Once During the Study n=368 participants at risk All patients received at least once Edoxaban during the study were included in the group. Adverse events which happened when the patients received Edoxaban were reported in this group. Patients can take any Antithrombotic treatments during the study. Adverse events were reported in the treatment group a patient actually received when the adverse event happened. Hence, the treatment groups in the adverse events section are not mutually exclusive.	Acetylsalicylic Acid (ASA) - at Least Once During the Study n=1940 participants at risk All patients received at least once Acetylsalicylic acid (ASA) during the study were included in the group. Adverse events which happened when the patients received Acetylsalicylic acid (ASA) were reported in this group. Patients can take any Antithrombotic treatments during the study. Adverse events were reported in the treatment group a patient actually received when the adverse events happened. Hence, the treatment groups in the adverse events section are not mutually exclusive.	Antiplts Other Than ASA - at Least Once During the Study n=427 participants at risk All patients received at least once Antiplts other than Acetylsalicylic acid (ASA) during the study were included in the group. Adverse events which happened when the patients received Antiplts other than ASA were reported in this group. Patients can take any Antithrombotic treatments during the study. Adverse events were reported in the treatment group a patient actually received when the adverse events happened. Hence, the treatment groups in the adverse events section are not mutually exclusive.
Blood and lymphatic system disorders Anaemia	0.17% 4/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.21% 7/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 7/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.37% 11/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.31% 6/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Blood and lymphatic system disorders Blood loss anaemia	0.08% 2/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.09% 3/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Blood and lymphatic system disorders Hypochromic anaemia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Blood and lymphatic system disorders Microcytic anaemia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Blood and lymphatic system disorders Splenic haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Atrial fibrillation	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Atrial thrombosis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Bradycardia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Cardiac arrest	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Cardiac failure	0.08% 2/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 4/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Cardiac failure congestive	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Cardiac tamponade	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Cardiac ventricular thrombosis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Hypertensive cardiomyopathy	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Mitral valve incompetence	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Cardiac disorders Myocardial infarction	0.08% 2/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Ear and labyrinth disorders Vertigo	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Eye disorders Eye haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Eye disorders Retinal artery embolism	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Abdominal pain	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Acute abdomen	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Anal haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Barrett's oesophagus	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Colitis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Colitis ischaemic	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Diarrhoea	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Diarrhoea haemorrhagic	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Discoloured vomit	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Diverticulum intestinal	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Duodenal ulcer haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Dyspepsia	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastric haemorrhage	0.08% 2/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastric ulcer	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastric ulcer haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastritis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastroduodenal ulcer	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.34% 8/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.31% 10/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.54% 14/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.20% 6/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.54% 2/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.62% 12/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 1/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Haematemesis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Haematochezia	0.08% 2/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Hiatus hernia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Intestinal ischaemia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Intra-abdominal haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Large intestine perforation	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.34% 8/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.18% 6/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.16% 4/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.15% 3/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.70% 3/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Mallory-Weiss syndrome	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Melaena	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 3/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Mesenteric haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Nausea	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Oesophageal ulcer haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Peptic ulcer	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Peritoneal haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Rectal haemorrhage	0.21% 5/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.16% 4/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Retroperitoneal haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Small intestinal haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.17% 4/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.37% 12/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 7/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.17% 5/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.70% 3/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Vomiting	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Gastrointestinal disorders Vomiting projectile	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Asthenia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Death	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.47% 2/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Medical device site haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Multiple organ dysfunction syndrome	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Non-cardiac chest pain	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Puncture site haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Sudden death	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Suprapubic pain	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
General disorders Vessel puncture site haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Hepatobiliary disorders Cholecystitis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Hepatobiliary disorders Hepatic failure	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Bronchitis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Cystitis	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Diverticulitis intestinal haemorrhagic	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Empyema	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Gastroenteritis	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Pneumonia	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Urinary tract infection	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Infections and infestations Urosepsis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Anaemia postoperative	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Contusion	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Extradural haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Fall	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 4/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Head injury	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Overdose	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Post procedural haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Post procedural haematuria	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 1/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 1/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Procedural haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Splenic injury	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Subcutaneous haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Subdural haematoma	0.13% 3/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.15% 5/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Subdural haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.09% 3/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Traumatic haematoma	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Traumatic haemothorax	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Injury, poisoning and procedural complications Traumatic renal injury	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Investigations Bleeding time prolonged	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Investigations International normalised ratio increased	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.15% 5/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Investigations Liver function test increased	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Investigations Occult blood	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Investigations Transaminases increased	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Musculoskeletal and connective tissue disorders Haemarthrosis	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Musculoskeletal and connective tissue disorders Haematoma muscle	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Musculoskeletal and connective tissue disorders Muscle haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrointestinal carcinoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Ataxia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Basal ganglia haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Brain injury	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Cerebellar haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Cerebellar infarction	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Cerebellar stroke	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Cerebral haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Cerebral haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.25% 8/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 3/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Cerebral infarction	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Cerebrovascular accident	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Embolic stroke	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Haemorrhage intracranial	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 4/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Haemorrhagic stroke	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.09% 3/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.16% 4/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 3/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Haemorrhagic transformation stroke	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Headache	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Intracranial haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Ischaemic cerebral infarction	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 1/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Ischaemic stroke	0.29% 7/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.15% 5/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 3/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.14% 4/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.15% 3/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.47% 2/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Subarachnoid haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.08% 2/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Syncope	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Transient ischaemic attack	0.17% 4/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.18% 6/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 3/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.14% 4/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.15% 3/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Nervous system disorders Vascular dementia	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Psychiatric disorders Anxiety	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Acute kidney injury	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Haematuria	0.13% 3/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.25% 8/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 6/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.17% 5/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 2/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Haemorrhage urinary tract	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Hypertensive nephropathy	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Nephrotic syndrome	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Renal haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Renal infarct	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Renal injury	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Ureterolithiasis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Urinary retention	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Renal and urinary disorders Urogenital haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 4/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Reproductive system and breast disorders Breast haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Reproductive system and breast disorders Uterine haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Reproductive system and breast disorders Vaginal haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.13% 3/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.49% 16/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 6/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.24% 7/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.27% 1/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.21% 4/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.07% 2/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Respiratory, thoracic and mediastinal disorders Haemothorax	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.06% 2/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Respiratory, thoracic and mediastinal disorders Respiratory tract haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Skin and subcutaneous tissue disorders Haemorrhage subcutaneous	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Aortic aneurysm rupture	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Arterial haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Embolism arterial	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Haematoma	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.25% 8/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.14% 4/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 1/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Haemorrhage	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.12% 4/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.04% 1/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.10% 3/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Ischaemia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.05% 1/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Peripheral embolism	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Peripheral ischaemia	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Shock haemorrhagic	0.04% 1/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Subgaleal haematoma	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Venous haemorrhage	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 1/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.23% 1/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.
Vascular disorders Deep vein thrombosis	0.00% 0/2385 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/3258 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/2576 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.03% 1/2934 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/368 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/1940 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.	0.00% 0/427 • From baseline visit until study completion or discontinuation, up to 3 years of follow-up. Enrolled and treated: All patients entered in the electronic data capture system who signed the informed consent and treated with at least once with the study treatments. Patients who were prescribed the combinations of oral anticoagulants at enrollment were excluded as no specific treatment can be defined for this group. For patients from the 'No treatment-initial' group, only their adverse events that happened when receiving certain treatment were reported in the respective treatment group.

Other adverse events

Adverse event data not reported

Additional Information

Boehringer Ingelheim Call Center

Boehringer Ingelheim

Phone: 1-800-243-0127

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER